Create accountLogin

Recent searches

No recent searches

Search options

Not available on mstdn.science.
mstdn.science is one of the many independent Mastodon servers you can use to participate in the fediverse.
http://mstdn.science is a place for scientists and science enthusiasts to discuss research and topics surrounding our work.

Administered by:

Server stats:

562
active users

mstdn.science: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.8

TumorBoardTuesday

RT @JohnEbbenMDPhD
A huge thanks to @KlempnerSam for an extraordinarily helpful discussion looking at Claudin 18.2 as a target in & .

Looking forward to readouts on IO combinations- hoping this can be a new option for pts w aggressive GI malignancy. twitter.com/JohnEbbenMDPhD/sta

TwitterJohnathan Ebben MD, PhD on Twitter“@TumorBoardTues @KlempnerSam @MPishvaian @KoheiShitara @SteveMaronMD @SunnieSKim @LizzySmyth1 @Thalcin @ShoSatoMD1 2/5 #TumorBoardTuesday Thurs Case🎀 ➡️We have a new feature - 🎥 TBT in a video Quick 📽️ take on Claudin 18.2 as a🎯in gastric/GEJ adenocarcinomas Our recommended algorithm for now (gastric/GEJ malignancy)- check: 🔹dMMR status 🔹PD-L1 CPS 🔹HER2 🔹(Claudin18.2 coming soon?)”
Dec 09, 2022, 07:46 PM·Quiet public·Moa
0boosts·0favorites
ExploreLive feeds
About